Terumo Corporation
Stock Price Chart
2026/08/21 UpdatedPrice Trend
2026/08/21 UpdatedPrice & Trading Details
2026/08/21 UpdatedPRICE
TRADING
Analyst Recommendations 14 analysts
Updated 2026/08/01Earnings Calendar
Updated 2026/08/01Recent Earnings
| Date | EPS Est. | EPS Actual | Surprise |
|---|---|---|---|
| 2026/05/15 | ¥15.01 | ¥17.87 | +19.1% |
| 2026/02/13 | ¥21.50 | ¥22.14 | +3.0% |
| 2025/11/12 | ¥24.28 | ¥23.76 | -2.1% |
| 2025/08/07 | ¥24.40 | ¥28.37 | +16.3% |
Shareholder Composition
Updated 2026/08/01Top Mutual Funds / ETFs
Updated 2026/08/01Major Holders
Updated 2026/08/01| Fund Name | Ownership | Shares | Change |
|---|---|---|---|
|
VANGUARD STAR FUNDS-Vanguard Total International Stock Index Fund
|
21.0M | +0.11% | |
|
MFS Series Trust XVII-MFS International Equity Fund
|
18.5M | +45.25% | |
|
VANGUARD TAX-MANAGED FUNDS-Vanguard Developed Markets Index Fund
|
13.9M | +2.32% | |
|
MFS SERIES TRUST X-MFS International Intrinsic Value Fund
|
13.5M | +1.00% | |
|
MFS SERIES TRUST X-MFS International Growth Fund
|
13.3M | 0.00% | |
|
iShares Trust-iShares Core MSCI EAFE ETF
|
9.8M | +1.59% |
| Institution | Ownership | Shares | Change |
|---|---|---|---|
|
Pacer Advisors, Inc.
|
25.0K | +52.03% |
Dividend History
Updated 2026/08/16| Year | Dividend | Change |
|---|---|---|
| 2026 | ¥15 | -46.4% |
| 2025 | ¥28 | +16.7% |
| 2024 | ¥24 | +11.6% |
| 2023 | ¥22 | +16.2% |
| 2022 | ¥19 | - |
Financial Performance
2026/08/16 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥703,303M | ¥820,209M | ¥921,863M | ¥1,036,171M |
| Gross Profit | ¥369,341M | ¥417,369M | ¥479,174M | ¥560,670M |
| Operating Income | ¥115,960M | ¥117,333M | ¥140,095M | ¥157,670M |
| Pretax Income | ¥117,462M | ¥120,153M | ¥143,604M | ¥160,821M |
| Net Income | ¥88,813M | ¥89,325M | ¥106,374M | ¥116,978M |
| EPS | ¥58.69 | ¥59.48 | ¥71.47 | ¥78.99 |
| Operating Margin | 16.49% | 14.31% | 15.20% | 15.22% |
| Balance Sheet | ||||
| Total Assets | ¥1,473,693M | ¥1,602,225M | ¥1,831,402M | ¥1,828,393M |
| Total Equity | ¥1,012,313M | ¥1,111,063M | ¥1,327,090M | ¥1,368,535M |
| Total Liabilities | ¥461,380M | ¥491,162M | ¥504,312M | ¥459,858M |
| Cash | ¥205,251M | ¥187,322M | ¥204,883M | ¥221,872M |
| Interest-bearing Debt | ¥225,996M | ¥231,937M | ¥231,848M | ¥174,838M |
| Equity Ratio | 68.69% | 69.35% | 72.46% | 74.85% |
| D/E Ratio | 0.22 | 0.21 | 0.17 | 0.13 |
| Cash Flow | ||||
| Operating CF | ¥141,467M | ¥117,536M | ¥146,330M | ¥210,802M |
| Investing CF | -¥78,454M | -¥59,121M | -¥81,472M | -¥82,481M |
| Financing CF | -¥70,879M | -¥86,559M | -¥62,079M | -¥108,766M |
| Free CF | ¥67,362M | ¥45,363M | ¥67,556M | ¥128,437M |
| Efficiency | ||||
| ROE | 8.77% | 8.04% | 8.02% | 8.55% |
| ROA | 6.03% | 5.58% | 5.81% | 6.40% |
Latest IR Information
-
Notice of decision not to specify the name of Terumo Capital Management Pte. Ltd. individually
Based on the plan to implement a capital reduction, a policy to not individually disclose the name of Terumo Capital Management Pte. Ltd. has been decided. Capital reduction date is August 21, 2026; liquidation date is to be determined. Please...
Read more -
Resolution to Dispose of Treasury Stock for Restricted Stock Compensation|July 2026
Terumo resolved to dispose of 116,206 shares of treasury stock for restricted stock compensation, providing approximately ¥253.3 million to the allottees.
Read more -
【Terumo】Enhancing Corporate Value through Stock Option Issuance | July 16, 2026
Terumo plans to issue new stock acquisition rights to management executives and Fellows to drive stock price increases and enhance corporate value. The total allocation is based on planned allotments, with the exercise period from August 5, 2026, to August...
Read more
Latest News (5 items)
-
Average Analyst Rating: strong_buy
Average Target Price: ¥3,023
Rating Score: 1.50 (Based on 14 analysts)
※1=Strong Buy, 5=Strong Sell
Company Information
About
Terumo Corporation engages in the manufacture and sale of medical products and equipment in Japan, Europe, China, the United States, Asia, and internationally. The company operates through four segments: Cardiac and Vascular Company, Medical Care Solutions Company, Blood and Cell Technologies Company, and Terumo Organ Technologies. The Cardiac and Vascular Company segment offers angiographic guidewires, angiographic catheters, introducer sheaths, vascular closure devices, PTCA balloon catheters, coronary stents, self-expanding peripheral stents, intravascular ultrasound systems, imaging catheters, and others; coils, stents, and intrasaccular devices for treating cerebral aneurysm; embolization systems, aspiration catheters, and clot retrievers for treating ischemic stroke and others; oxygenators, cardio-pulmonary bypass systems, and others; and artificial vascular stent grafts, and others. The Medical Care Solutions Company segment provides syringes, infusion pumps, syringe pumps, infusion lines, I.V. solutions, peritoneal dialysis fluids, pain management adhesion barriers, and others; blood glucose monitoring systems, disposable needles for pen-injector, insulin patch pumps, blood pressure monitors, digital thermometers, and others; and contract manufacturing of prefilled syringes, devices to pharmaceutical companies for use in drug kits, such as prefillable syringes, needles for pharmaceutical packaging business, and others. The Blood and Cell Technologies Company segment offers blood bags, component collection systems, automated blood processing systems, pathogen reduction systems, centrifugal apheresis systems, cell expansion systems, and others. The Terumo Organ Technologies segment provides organ preservation devices. The company was formerly known as Sekisen Ken-onki Corporation and changed its name to Terumo Corporation in October 1974. Terumo Corporation was incorporated in 1921 and is headquartered in Shibuya, Japan.